US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

248.72

-0.9300-0.37%

Post-market: 250.001.28+0.51%19:59 EDT

Volume:344.92K

Turnover:86.47M

Market Cap:565.71M

PE:- -

High:259.39

Open:256.76

Low:244.53

Close:249.65

52wk High:341.93

52wk Low:100.18

Shares:2.27M

Float Shares:2.27M

Volume Ratio:1.06

T/O Rate:15.16%

Dividend:0.90

Dividend Rate:0.36%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Under the Radar: Grail Shares Surge on FDA Results

Health Care up on Drug Breakthrough Hopes - Health Care Roundup

Health Care Roundup: Market Talk

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Sector Update: Healthcare

MT Newswires Live

Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection

MT Newswires Live

Wall Street Analysts Are Bullish on Top Healthcare Picks

Valneva (VALN) Gets a Buy from H.C. Wainwright

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live

Health Care Roundup: Market Talk

Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)

FDA Platform Designation Strengthens AdenoVerse Outlook; Analyst Maintains Buy Rating and $18 Price Target on Precigen

Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review from FDA

Grail rallies after FDA releases briefing documents for Galleri test review

Dr. Agarwal’s Health Care clears all resolutions at virtual 16th AGM

Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB)

Health Insurance Quality Upgrade: One Year On, Product Innovation and Regulatory Correction Advance Side by Side, With Payment-Side Momentum Building

Sector Update: Healthcare

MT Newswires Live

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA

DRI Healthcare to Buy Tavapadon Royalty for $316 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/LABU/news?page=19"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":248.72,"timestamp":1790971200000,"preClose":249.65,"halted":0,"volume":344920,"hourTrading":{"tag":"盘后","latestPrice":250,"preClose":248.72,"latestTime":"19:59 EDT","volume":5030,"amount":1253587.6992,"timestamp":1790985599756,"change":1.28,"changeRate":0.005146,"amplitude":0.005179},"delay":0,"changeRate":-0.003725215301422018,"floatShares":2274486,"shares":2274486,"eps":0,"marketStatus":"Market Closed","change":-0.93,"latestTime":"10-02 16:00:00 EDT","open":256.755,"high":259.39,"low":244.53,"amount":86471147.3688,"amplitude":0.059523,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":249.65,"sharesOutstanding":3074486,"nav":248.875,"aum":566062383.8,"dividendRate":0.003633,"bidAskSpread":0.003777,"preHourTrading":{"tag":"盘前","latestPrice":256,"preClose":249.65,"latestTime":"09:27 EDT","volume":5553,"amount":1438964.4383999999,"timestamp":1790947678782,"change":6.35,"changeRate":0.025436,"amplitude":0.043381},"postHourTrading":{"tag":"盘后","latestPrice":250,"preClose":248.72,"latestTime":"19:59 EDT","volume":5030,"amount":1253587.6992,"timestamp":1790985599756,"change":1.28,"changeRate":0.005146,"amplitude":0.005179},"volumeRatio":1.055472560797593,"impliedVol":0.9378,"impliedVolPercentile":0.5618},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2274486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.055472560797593,"shares":2274486,"dividePrice":0.9037,"high":259.39,"amplitude":0.059523,"preClose":249.65,"low":244.53,"week52Low":100.18,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":248.72,"eps":0,"divideRate":0.003633,"volume":344924,"delay":0,"ttmEps":0,"open":256.755,"prevYearClose":159.39,"prevWeekClose":252.47,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":252.47,"twentyDayClose":305.86,"sixtyDayClose":324.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:19,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669556196","title":"Under the Radar: Grail Shares Surge on FDA Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669556196","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669556196?lang=en_us&edition=fundamental","pubTime":"2026-09-22 06:57","pubTimestamp":1790031420,"startTime":"0","endTime":"0","summary":"Shares of Grail surged 34% Monday after the Food and Drug Administration released documents ahead of an advisory committee meeting Wednesday that will help determine whether the FDA approves the company's multi-cancer blood test.Galleri looks for chemical tags on DNA that tumors shed into the blood. The test flags a cancer signal and predicts the organ where the cancer is present. Grail has sold it by prescription since 2021, but the FDA has never approved a test that screens for multiple cancers.In a U.S. study of more than 25,000 adults, Galleri wrongly flagged cancer in 0.15% of healthy people. The test missed most cancers. It caught roughly one-third of those diagnosed within a year, in that study and in a U.K. trial of about 142,000 people. In the U.K. trial, it caught 14% of Stage 1 cancers, the earliest stage. The FDA has asked advisers whether those numbers justify calling Galleri an \"early detection\" test.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","GRAL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669193492","title":"Health Care up on Drug Breakthrough Hopes - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2669193492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669193492?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:03","pubTimestamp":1790024580,"startTime":"0","endTime":"0","summary":"Health-care companies rose amid hopes for new drug breakthroughs.Shares of Moderna surged by more than 10%, and the vaccine maker has now risen more than fivefold for the year to date, after abstracts","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","XLV","LABU","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669193629","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2669193629","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669193629?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:50","pubTimestamp":1790023800,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0655 ET - Lundbeck's study results for epilepsy drug candidate b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","BK4588","LABU","ITM","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669987061","title":"Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2669987061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669987061?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:15","pubTimestamp":1790021700,"startTime":"0","endTime":"0","summary":"Jemperli global net sales of $644 million (480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365866/0/en/anaptys-announces-second-quarter-and-transitional-fiscal-year-2026-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669081160","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669081160","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669081160?lang=en_us&edition=fundamental","pubTime":"2026-09-22 03:21","pubTimestamp":1790018463,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF  adding 0.8%.The iShares Biotechnology ETF  climbed 1.4%.In corporate news, Eli Lilly's  oral drug Foundayo now makes up one-third of new GLP-1 pill patients, CNBC reported, citing CEO Dave Ricks. Lilly broke ground on a $6.5 billion Houston manufacturing plant expected to be operational by 2030, the report also said. Lilly shares rose 0.9%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4JS1V06.HKD","LU2462591350.SGD","LU1548497426.USD","VHT","LU1035775433.USD","OZEM","SG9999018857.SGD","LU1629891620.HKD","BK4007","LU1057294990.SGD","ILDR","LU0096364046.USD","LU2461242641.AUD","LU0203201768.USD","LU1868836591.USD","LU1323610961.USD","IE00BN29S564.USD","MEDX","LU0417517546.SGD","LU1127390331.HKD","LU1917777945.USD","LU1974910355.USD","LU2237443465.HKD","LU1291159041.SGD","LU1023059063.AUD","LU1989771016.USD","LU0133085943.USD","LU0158827948.USD","LU2112291526.USD","LU2746668461.USD","IE0004445015.USD","LU0823434583.USD","LU1093756168.USD","LU2063271972.USD","LU0786609619.USD","LU2357305700.SGD","IE00BFSS7M15.SGD","PJP","LU0672654240.SGD","LU1804176565.USD","IE00B1XK9C88.USD","LU2746668974.SGD","LU0079474960.USD","LU0354030511.USD","IE0001KFT4U8.USD","LU2552382132.HKD","LU1280957306.USD","BK4533","JDOC","AGNG","LU1232071149.USD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU0823416689.USD","CURE","LLYX","LU0289739699.SGD","LU1988902786.USD","LU2750360641.GBP","WDNA","LU0238689110.USD","LU2265009873.SGD","LU0158827781.USD","LU1814569148.SGD","LU2108987350.USD","LU2023250504.SGD","LU2089283258.USD","LU2750360997.AUD","IE0002141913.USD","LU0109391861.USD","IE00B2B36J28.USD","GDOC","LU1093756325.SGD","IE00BK4W5M84.HKD","LU0122379950.USD","LU1267930730.SGD","LLII","BK4534","LU0061475181.USD","SG9999001176.SGD","BK4588","LU0266013472.USD","LU2237443382.USD","LU2168564495.EUR","LU0106261372.USD","LU2168563687.JPY","IE00BKPKM429.USD","LU2168564222.USD","SG9999017495.SGD","LU2491049909.HKD","IE0005OL40V9.USD","SG9999013999.USD","LU1064131342.USD","LLYZ","IE00BJJMRZ35.SGD","LU1366192091.USD","LU0316494557.USD","LU1691799644.USD","LU2111349929.HKD","LU2361045086.USD","IE00BJJMRX11.SGD","ELIS","TRUH","IE00B1BXHZ80.USD","LU1720051108.HKD","HRTS","LU2211815571.USD","LU0683600562.USD","LU0787776722.HKD","MEDI","LU2602419157.SGD","LU0354030438.USD","LU0708995401.HKD","LU2237443549.SGD","SG9999001176.USD","IE00BWXC8680.SGD","LU0820561909.HKD","BK4599","LU0210536198.USD","LU1551013342.USD","LU2106854487.HKD","LU1712237335.SGD","LU1868837136.USD","LU2271345857.HKD","LU2089984988.USD","LU2552382215.SGD","SG9999014898.SGD","LU2471134796.USD","IE00BJJMRY28.SGD","IE00BKDWB100.SGD","LU0471298777.SGD","LU1061106388.HKD","LU2324357040.USD","LU2237443978.SGD","LU2360106947.USD","FTXH","LU2213496289.HKD","LU0094547139.USD","LU2471134879.HKD","LU2361044949.HKD","SGXZ51526630.SGD","SGXZ99366536.SGD","LU2417539215.USD","LU0889565916.HKD","LU0820562030.AUD","LU0820561818.USD","CANC","GB00BDT5M118.USD","IE00B7KXQ091.USD","LU0256863811.USD","SG9999014914.USD","LU2023250330.USD","BK4581","BK4516","LU0345770308.USD","LU0345770993.USD","FHLC","LU0385154629.USD","LU0964807845.USD","LU1623119135.USD","LU0198837287.USD","LU0174119429.USD","LU0058720904.USD","IHE","IXJ","LU0466842654.USD","SGXZ31699556.SGD","XLV","LU1983299246.USD","THNR","LU2087625088.SGD","LU0320765059.SGD","LU1868836757.USD","LU2028103732.USD","LU2471134952.CNY","LU1145028129.USD","SG9999014906.USD","SG9999014880.SGD","IE00BK4W5L77.USD","LU0456855351.SGD","LU1868837300.USD","LU0882574055.USD","LLY","LU0823434740.USD","LU0323591593.USD","LU2361044865.SGD","LU2236285917.USD","LU2023251221.USD","SG9999015986.USD","RXL","LU2471134523.USD","IBB","SG9999018865.SGD","SGXZ57979304.SGD","MHIP","LU0203202063.USD","IE00BFSS8Q28.SGD","LU1069344957.HKD","LU2462157665.USD","IE00B4R5TH58.HKD","PPH","LU2468319806.SGD","IE0009355771.USD","LU2756315318.SGD","TMED","IE00BJT1NW94.SGD","LU0943347566.SGD","LU1720051017.SGD","LU0353189680.USD","LU2896262040.SGD","LU2756315664.SGD","LU0097036916.USD","LU1868836914.USD","LU0114720955.EUR","LU2264538146.SGD","SG9999015952.SGD","LU2491050071.SGD","ELIL","LU0353189763.USD","LU2168564065.EUR","IE00B775H168.HKD","LU0006306889.USD","LU2456880835.USD","LU2237438978.USD","SGXZ81514606.USD","LU0320765992.SGD","LU1551013425.SGD","LU2552382058.USD","LU2089284900.SGD","LU1979441026.SGD","XBI","SG9999015945.SGD","LU0109394709.USD","LU2491050154.USD","LU0256863902.USD","IE00BJLML261.HKD","IYH","LABU","IE0004445239.USD","SG9999015978.USD","LU2237443622.USD","LU2237443895.HKD","LU0225283273.USD","LU0432979614.USD","LU0234572021.USD","LU0882574139.USD","LU2168564149.EUR","BK4585","LU0640476718.USD","LU0689472784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160658","title":"Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160658","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160658?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:24","pubTimestamp":1790015049,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals  shares rose more than 10% in Monday trading after the company said Friday the US Food and Drug Administration approved its lanreotide injection, 120 mg/0.5 mL.The company said it will immediately launch the product, which references SOMATULINE Depot and received Competitive Generic Therapy designation from the FDA.Lanreotide injection is indicated for the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors and carcinoid syndrome, according to a statement.Price: 20.62, Change: +1.91, Percent Change: +10.18","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4585","AMRX","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160585","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160585?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:00","pubTimestamp":1790013659,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN), Abeona Therapeutics (ABEO) and AbSci ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-343?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-343?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","BK4588","AGEN","BK4139","ABEO","BK4137","LABU","BK4581","LU0029874061.USD","LU0128526141.USD","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167022","title":"Valneva (VALN) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167022?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:57","pubTimestamp":1790013425,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Valneva today and set a price target of $18.00. Folkes covers the Healthcare sect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/valneva-valn-gets-a-buy-from-h-c-wainwright-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/valneva-valn-gets-a-buy-from-h-c-wainwright-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4581","BK4585","BK4139","VALN","LABU","XBI","XLV","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669538167","title":"Exchange-Traded Funds Rise as US Equities Advance After Midday","url":"https://stock-news.laohu8.com/highlight/detail?id=2669538167","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669538167?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:07","pubTimestamp":1790010473,"startTime":"0","endTime":"0","summary":"Broad Market IndicatorsBroad-market exchange-traded funds IWM and IVV were higher. Actively traded Invesco QQQ Trust (QQQ) added 2.5%.US equity indexes rose as mega-cap technology names perked up amid","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTH","BITI","BFAP","XAGUSD.FOREX","BK4585","BITU","IYJ","QBF","XBI","PSQ","BK4588","TQQQ","BTF","AGQ","BCCC","IAU","BTCO","XLE","ETCO","FAZ","VIS","IBIT","ETHD","IYH","LABU","BTCI","BTC","CBOA","BITB","SLV","BTCC","CBTY","QMAR","TETH","TQQY","CBXJ","BITX","QQQX","BGLD","EZBC","UNG","MAXI","BRRR","DULL","XLPU","SOXS","SHNY","SBIT","DGP","BTC.USD.CC","IBB","XAUUSD.FOREX","ETQ","GCPU","BK4593","DEFI","NOCT","BETH","IYE","BAGY","QLD","IGM","GLDY","BK4504","BK4550","XLPD","NJAN","HODL","CBTO","RETL","XRT","SETH","SOXX","NJUL","XLF","BTCW","ESK","BFJL","NAPR","XBTY","BK4561","BK4534","XLV","MNRS","BK4547","CBXY","XSD","BETE","QID","CBOJ","BTRN","BTCZ","VDC","XLI","GPIQ","GLD","BITY","DZZ","IAUM","YBTC","QQQM","BPI","DGZ","BTCL","FBTC","USG","ETH.USD.CC","OUNZ","BK4581","BAR","SOXL","YGLD","QQQ","VHT","GLDM","CBTJ","SGOL","UGL","BITO","ZSL","TECL","EETH","AAAU","CBTA","GBTC","ETHT","IYW","XLK","USO","SIVR","IGLD","CBXO","CBOY","FGDL","UCO","ETH","GLL","ARKB","SQQQ","DFII","CBOO","KGLD","XLY","NDX","BK4570","QDEC","XLP","CBXA","FAS","IAUI","SCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669629941","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2669629941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669629941?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:20","pubTimestamp":1790007600,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0655 ET - Lundbeck's study results for epilepsy drug candidate b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4588","LABU","XLV","BK4581","ITM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162646","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162646?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:10","pubTimestamp":1790007009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN). NewAmster...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","XBI","BK4137","BK4585","BK4581","BK4588","LPCN","HCSG","LU0029874061.USD","LU0128526141.USD","NAMS","BK4007","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316476","title":"FDA Platform Designation Strengthens AdenoVerse Outlook; Analyst Maintains Buy Rating and $18 Price Target on Precigen","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316476","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316476?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:55","pubTimestamp":1790006120,"startTime":"0","endTime":"0","summary":"In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Precigen, with a price target of $18.00. Swayamp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fda-platform-designation-strengthens-adenoverse-outlook-analyst-maintains-buy-rating-and-18-price-target-on-precigen-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fda-platform-designation-strengthens-adenoverse-outlook-analyst-maintains-buy-rating-and-18-price-target-on-precigen-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","PGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669645164","title":"Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669645164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669645164?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:28","pubTimestamp":1790004480,"startTime":"0","endTime":"0","summary":"Shares of Grail soared ahead of the diagnostic company's meeting with the Food and Drug Administration this week to evaluate premarket approval for its landmark blood test designed to spot multiple ty","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","LABU","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164979","title":"Grail rallies after FDA releases briefing documents for Galleri test review","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164979?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:20","pubTimestamp":1790004023,"startTime":"0","endTime":"0","summary":"Shares of Grail (GRAL) are up $24.76, or 31%, to $105.53 after the FDA posted briefing documents ahead of the Molecular and Clinical Genetics Panel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-rallies-after-fda-releases-briefing-documents-for-galleri-test-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-rallies-after-fda-releases-briefing-documents-for-galleri-test-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","GRAL","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169193","title":"Dr. Agarwal’s Health Care clears all resolutions at virtual 16th AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169193?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:50","pubTimestamp":1789998652,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Dr. Agarwal’s Health Care Ltd. ( ($IN:AGARWALEYE) ). Dr. Agarwal’s Health Care Limited held its 16th Annual Gen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dr-agarwals-health-care-clears-all-resolutions-at-virtual-16th-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dr-agarwals-health-care-clears-all-resolutions-at-virtual-16th-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169130","title":"Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169130?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:50","pubTimestamp":1789998610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Charles River Labs (CRL) and AgomAb Therapeutics NV ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-charles-river-labs-crl-and-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-charles-river-labs-crl-and-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DIVL","BK4530","ARMH","CRL","HCSG","DINT","AADR","XLV","BK4585","CVY","BK4581","BK4588","LU0029874061.USD","LU0757428866.USD","XBI","LU1815336091.USD","BK4137","BK4121","LABU","LU0128526141.USD","BK4007","APIE","AGMB","IE00BFMHRM44.USD","LU0390134368.USD","SAPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171791963","title":"Health Insurance Quality Upgrade: One Year On, Product Innovation and Regulatory Correction Advance Side by Side, With Payment-Side Momentum Building","url":"https://stock-news.laohu8.com/highlight/detail?id=1171791963","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171791963?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:30","pubTimestamp":1789997440,"startTime":"0","endTime":"0","summary":"A year ago, the financial regulatory authority issued guidance on driving high-quality development in health insurance, laying out a transformation roadmap for the industry. Reviewing the past twelve...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669668841","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669668841","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669668841?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:01","pubTimestamp":1789995684,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Monday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  down a slight 0.1%.Novo Nordisk  is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported, citing the company's investors. Shares of Novo Nordisk were down 4.7% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","LU1093756325.SGD","BK4599","LABU","IE00BZ1G4Q59.USD","BK4585","NVOH","LU0154236417.USD","NVOX","OZEM","BK4007","PPH","LU1093756168.USD","NVOC","IBB","BK4581","XBI","BK4588","IE00BKVL7J92.USD","NVO","XLV","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669165511","title":"Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669165511","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669165511?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:30","pubTimestamp":1789993800,"startTime":"0","endTime":"0","summary":"Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 millionregi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365465/0/en/clene-announces-closing-of-4-million-registered-direct-offering-extending-capital-runway-beyond-fda-decision-on-cnm-au8-nda.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4104","IE0009354923.USD","LU1923621640.USD","LU2125910179.SGD","LU1165135440.EUR","LU2125910336.SGD","LU2413666004.HKD","LU2229751404.USD","BK4588","BK4539","LU2089279066.USD","LU1620156213.USD","LU2413665964.HKD","LU1596574779.USD","LU1543694498.USD","LU1721427968.SGD","CNM","BK4585","LU1620156130.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669168991","title":"DRI Healthcare to Buy Tavapadon Royalty for $316 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669168991","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669168991?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:33","pubTimestamp":1789990380,"startTime":"0","endTime":"0","summary":"DRI Healthcare Trust reached a $316 million deal to buy certain royalty participation rights in U.S. net sales of tavapadon, an investigational Parkinson's disease drug candidate.The Toronto-based pharmaceutical royalty company on Monday said it entered into purchase agreements to acquire the royalty participation rights from funds managed by Bain Capital and NovaQuest Capital Management, subject to approval of tavapadon by the U.S. Food and Drug Administration.The acquisition will entitle DRI Healthcare to receive tiered royalty payments on annual U.S. net sales of tavapadon, at combined tiered, mid-single digit to low-double digit royalty rates. DRI Healthcare will also be entitled to receive certain sales milestone payments on first reaching certain cumulative U.S. net sales thresholds and four annual fixed payments of $23.4 million on the first four anniversaries of FDA approval of tavapadon. Aggregate receipts are subject to a contractual hard cap of $437.5 million.In August, DRI ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4137","HCSG","BK4585","LU0128526141.USD","XBI","LABU","XLV","LU0029874061.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":19,"totalSize":396,"code":"91000000","status":"200"}]}}